Exela Sciences Patent-Cliff Exposure & CMS Drug Spending Portfolio

Exela Sciences (US): 3 reconciled FDA prescription therapies, $23.1M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies3
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2039-01-01
2024 CMS Total Public Spend$23.1M
2024 Medicare Part D Spend$3.0M
2024 Medicaid Spend$20.1M
California HCAI SB 17 Filings1 WAC filings (max 26.3% 2-yr change)